ArticleJACC. Case reports2026
Percutaneous Left Atrial Appendage Balloon-Occlusive Aspiration Thrombectomy With Subsequent Occluder Implant.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is currently no standard clinical approach to patients in need of left atrial appendage (LAA) occlusion device with persistent LAA thrombus. The steerable, balloon-tipped SafeCross transseptal introducer system provides the opportunity for a novel approach to LAA thrombectomy by blockading the LAA os with its balloon tip, creating a closed system for embolic protection during aspiration. CASE SUMMARY: Consecutive patients from the Medical University of South Carolina were included who underwent balloon-occlusive aspiration thrombectomy (BOAT) of the LAA with the SafeCross system followed by LAA occlusion device implantation. DISCUSSION: Four patients, with a mean age of 79.5 ± 4.04 years and 75% male, were included. Balloon occlusion was achieved in 75% of cases during BOAT of the LAA. All cases resulted in successful aspiration of the LAA thrombus and subsequent successful placement of Watchman FLX Pro without periprocedural complications or adverse events at 45-day follow-up. TAKE-HOME MESSAGE: Our small case series demonstrates the feasibility of performing a transseptal LAA BOAT thrombectomy with the SafeCross transseptal system to facilitate LAA occluder implant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.